Related references
Note: Only part of the references are listed.Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors
Karin Leander et al.
CIRCULATION (2016)
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations
Hayato Tada et al.
CIRCULATION JOURNAL (2016)
Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese
S-H. Yang et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2016)
Cross-talk between LOX-1 and PCSK9 in vascular tissues
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2015)
PCSK9: A key factor modulating atherosclerosis
Sha Li et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
Rocco Romagnuolo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Removal of Plasma Mature and Furin-Cleaved Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein-Apheresis in Familial Hypercholesterolemia: Development and Application of a New Assay for PCSK9
Mika Hori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients
Ymene Nekaies et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2015)
Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease
Y. Zhang et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2015)
Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease The Atherosclerosis Risk in Communities ( ARIC) Study
Ron C. Hoogeveen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Amit V. Khera et al.
CIRCULATION (2014)
Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins
Arjan J. Kwakernaak et al.
CLINICAL BIOCHEMISTRY (2014)
The composition and metabolism of large and small LDL
Margaret R. Diffenderfer et al.
CURRENT OPINION IN LIPIDOLOGY (2014)
Lipoprotein(a) metabolism
Stefania Lamon-Fava et al.
CURRENT OPINION IN LIPIDOLOGY (2014)
Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis
Sha Li et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Frederick J. Raal et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies
Naif A. M. Almontashiri et al.
PLOS ONE (2014)
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial
Nihar R. Desai et al.
CIRCULATION (2013)
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Giuseppe Danilo Norata et al.
EUROPEAN HEART JOURNAL (2013)
Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
Tanja Kosenko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
Daniel Urban et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis
Tsuyoshi Nozue et al.
AMERICAN HEART JOURNAL (2012)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
Frederick Raal et al.
CIRCULATION (2012)
Development of a Homogeneous Assay for Measurement of Small Dense LDL Cholesterol
Yasuki Ito et al.
CLINICAL CHEMISTRY (2011)
Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population
Qin Cui et al.
ATHEROSCLEROSIS (2010)
Small Dense LDL Cholesterol and Coronary Heart Disease: Results from the Framingham Offspring Study
Masumi Ai et al.
CLINICAL CHEMISTRY (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
Jason S. Troutt et al.
JOURNAL OF LIPID RESEARCH (2010)
Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
Alexis Baass et al.
CLINICAL CHEMISTRY (2009)
Lipoprotein a: where are we now?
Konstantinos Tziomalos et al.
CURRENT OPINION IN CARDIOLOGY (2009)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population
Pia R. Kamstrup et al.
CIRCULATION (2008)
Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia
Tsuyoshi Nozue et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2008)
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Jun Li et al.
BIOCHEMICAL JOURNAL (2007)
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women - The EPIC-Norfolk Prospective Population study
Karim El Harchaoui et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
The proprotein convertases and their implication in sterol and/or lipid metabolism
Nabil G. Seidah et al.
BIOLOGICAL CHEMISTRY (2006)
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
SW Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia
S Sasaki et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Circulating oxidized low density lipoprotein levels - A biochemical risk marker for coronary heart disease
S Toshima et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Simple and practical sandwich-type enzyme immunoassay for human oxidatively modified low density lipoprotein using antioxidized phosphatidylcholine monoclonal antibody and antihuman apolipoprotein-B antibody
H Kohno et al.
CLINICAL BIOCHEMISTRY (2000)
Lipoprotein(a) in homozygous familial hypercholesterolemia
HG Kraft et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Share Paper
